Fadrozole
Fadrozole is a nonsteroidal aromatase inhibitor that is primarily used in the treatment of estrogen receptor-positive breast cancer. It works by inhibiting the enzyme aromatase, which is responsible for the conversion of androgens to estrogens. This reduction in estrogen levels can help slow the growth of certain types of breast cancer that require estrogen to grow.
Mechanism of Action[edit | edit source]
Fadrozole inhibits the aromatase enzyme, which is a key enzyme in the biosynthesis of estrogens. By blocking this enzyme, fadrozole reduces the production of estrogens from androgens in peripheral tissues. This leads to a decrease in circulating estrogen levels, which can help in the management of estrogen-dependent conditions such as breast cancer.
Clinical Uses[edit | edit source]
Fadrozole is primarily used in the treatment of estrogen receptor-positive breast cancer in postmenopausal women. It may also be used in other conditions where estrogen suppression is beneficial, although its use is less common compared to other aromatase inhibitors like anastrozole and letrozole.
Side Effects[edit | edit source]
Common side effects of fadrozole include:
Less common but more serious side effects can include:
Pharmacokinetics[edit | edit source]
Fadrozole is administered orally and is well-absorbed from the gastrointestinal tract. It undergoes hepatic metabolism and is excreted primarily in the urine. The half-life of fadrozole allows for once-daily dosing.
Comparison with Other Aromatase Inhibitors[edit | edit source]
Fadrozole is one of several aromatase inhibitors used in the treatment of breast cancer. Other commonly used aromatase inhibitors include anastrozole, letrozole, and exemestane. Each of these drugs has a slightly different mechanism of action and side effect profile, but all work to reduce estrogen levels in the body.
Research and Development[edit | edit source]
Research is ongoing to better understand the full potential of fadrozole in various estrogen-dependent conditions. Studies are also being conducted to compare its efficacy and safety profile with other aromatase inhibitors.
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
-
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD